biostudies-literatureUnknown41Kumar MS<h4>Background</h4>India accounts for one-fifth of the global hepatitis A virus (HAV) infections and half of HAV-related deaths. There is a lack of nationally representative population-based data on the endemicity of HAV to inform vaccination policy. We aimed to estimate the age-specific seroprevalence of HAV infection among individuals aged 6-30 years.<h4>Methods</h4>We used serum samples collected during the fourth national COVID-19 serosurvey conducted between 14 June and 6 July 2021 to estimate the seroprevalence of HAV infection. The survey was conducted in 70 randomly selected districts across 20 Indian states and one union territory. We tested the serum samples from individuals aged six to 30 years for IgG antibodies against HAV. We estimated the overall and state-specific seroprevaThe Lancet regional health. Southeast Asia100669https://www.ebi.ac.uk/biostudies/studies/S-EPMC12506519biostudies-literatureSeroprevalence of IgG antibodies against hepatitis-A infection among individuals aged 6-30 years in India, 2021: a nationwide population-based cross-sectional study.PMC12506519Behera SPSelvaraju SBhat JHaq IThakor MTuruk AKumar APKumar NChopra VChakrabarti ADeb AKKumar MSBhatnagar TKrishnan NNMurhekar MVDhatrak SSaravanakumar VJain AChaudhury AAnandhan BDwivedi GRSingh MBalachandar RSingh PAkula NDSingh RParvathi SSingh SDayal RTuruk JArlappa NDutta SDeval HChandrasekaran PAnbu MICMR serosurveillance groupSalim Khan SMLaxmaiah ANirmala ARChakraborty DKumar CPGSahay SVadhani SDBharti PKPalo SKNarain KJagjeevan BNaduvilethil STRajkumar HDevi KRGiridharan PSekar KRade KKotala NBMitra AVivian Thangaraj JWKalaiselvan AViramgami ARamesh TRangaraju CKhan AMMadhukar MKarunakaran TPanda SNarasimhaiah SYadav SBhargava BMurugan PAsthana SKanungo SSingh HBPandey AKSingh PKSrinivasan NSangwan RKPandey KDhikav VKant RPati SKalliath ABansal AKMahapatra AQurieshi MAVinod Kumar VGDas DMayandi SKRobinson ABhattacharya DSabarinathan RBangar SDBashir KChahal ASAndhalkar RKshatri JSfalseSeroprevalence of IgG antibodies against hepatitis-A infection among individuals aged 6-30 years in India, 2021: a nationwide population-based cross-sectional study.<h4>Background</h4>India accounts for one-fifth of the global hepatitis A virus (HAV) infections and half of HAV-related deaths. There is a lack of nationally representative population-based data on the endemicity of HAV to inform vaccination policy. We aimed to estimate the age-specific seroprevalence of HAV infection among individuals aged 6-30 years.<h4>Methods</h4>We used serum samples collected during the fourth national COVID-19 serosurvey conducted between 14 June and 6 July 2021 to estimate the seroprevalence of HAV infection. The survey was conducted in 70 randomly selected districts across 20 Indian states and one union territory. We tested the serum samples from individuals aged six to 30 years for IgG antibodies against HAV. We estimated the overall and state-specific seropreva2025-01-01T00:00:00Z2025 Oct2026-06-04T09:10:13.252Z2026-05-07T03:12:02.768ZS-EPMC125065194107035410.1016/j.lansea.2025.100669